Grants and Contributions:

Back to search
Title:
LAU-7b as next-generation COVID-19 therapeutic - COVID-19 Response-Stage 3 (TI): antiviral & Inflammation Controlling Therapeutic Drug Clinical Evaluation
Agreement Number:
1002706
Agreement Value:
$7,000,000.00
Agreement Date:
Feb 1, 2023 - Mar 31, 2025
Description:
The project is focusing on Phase 3 pivotal study of LAU-7b in moderate-to-severe hospitalized COVID-19 patients, and has a component allowing the transition to a new Phase 2 clinical development in mild-to-moderate non-hospitalized COVID-19 patients. LAU-7b is a next-generation COVID-19 antiviral that addresses the gap between early infection and critical COVID-19 disease, and aims for broad applicability at-home or in hospital. Because its host-directed mechanism, LAU-7b has the potential to work on all mutations of COVID-19, and other coronaviruses. Results from the Phase 2 pilot study showed 100% reduction in the risk of progression to mechanical ventilation and death in hospitalized moderate-to-severe patient.
Organization:
National Research Council Canada
Expected Results:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Location:
Montreal, Quebec, CA H3A 2R7
Reference Number:
172-2022-2023-Q4-1002706
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
835517442
Recipient Type:
For-profit organization
Additional Information:

This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days.

Amendment Date
Dec 3, 2024
Recipient's Operating Name:
Laurent Thérapeutiques
Recipient's Legal Name:
Laurent Pharmaceuticals Inc.
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments:
See Amendments